glp-1 obesity drug news october 9 2025 As interest in medication grows, scammers are tricking consumers with fake alternatives. Here's how to spot them. http://www.wtae.com/article/ weight-loss-scam-warning-fueled-by-glp-1-hype-ai-deepfakes/69917014 Lilly hikes revenue forecasts on

doi: 10.1016/S0887-2333(02)00087-5

Studies with longer follow-up duration are required to further investigate the potential factors associated with weight change after discontinuation of treatment

This type of program appeals to patients who want a more defined weight loss plan with physician review and ongoing oversight

2 Reward Eating, GLP-1 and Estrogen Reward eating is comprised of two categories, wanting and liking. 5 Liking is associated with the palatability of the food and wanting is food craving triggered by a cue or stimuli which then leads to motivation to obtain a specific type of food

S1D, GLP-1RA intervention was associated with a reduction in WHR when compared to metformin (MD = 0.03

Here is what the clinical evidence consistently shows: Significant, sustained weight loss The STEP clinical trials for semaglutide showed average weight loss of 14.9% of body weight over 68 weeks more than double the typical result from traditional dieting programs